Valuation: Intervacc AB

Market Cap 23Cr 2.25Cr 2.05Cr 1.9Cr 1.71Cr 3.22Cr 210.15Cr 3.35Cr 9.05Cr 113.43Cr 8.44Cr 8.26Cr 358.18Cr P/E 2026 *
-2.36x
P/E 2027 * -2.86x
Enterprise Value 15Cr 1.46Cr 1.33Cr 1.23Cr 1.11Cr 2.09Cr 136.42Cr 2.17Cr 5.88Cr 74Cr 5.48Cr 5.36Cr 232.52Cr EV / Sales 2026 *
7.22x
EV / Sales 2027 * 6.32x
Free-Float
82.02%
Yield 2026 *
-
Yield 2027 * -
1 day+2.68%
1 week-1.00%
Current month-10.62%
1 month-20.60%
3 months-38.17%
6 months-42.69%
Current year-25.32%
1 week 0.64
Extreme 0.645
0.73
1 month 0.64
Extreme 0.645
0.92
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
23/02/25 Free

Chief Financial Officer

9,29,208 1.2269%
17/02/25 Buy

Chief Executive Officer

1,35,000 0.1783%
17/02/25 Sell

Chief Executive Officer

2,78,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
+2.68%-1.00%-25.81%-88.25% 2.25Cr
-1.34%-3.09%+56.10%+68.83% 6.55TCr
-0.09%-3.05%+7.80%+90.73% 5.89TCr
+0.62%+0.42%+26.28%+87.23% 5.52TCr
-2.34%-3.90%+10.90%+115.97% 4.61TCr
+0.09%-6.08%+18.67%+25.90% 4.25TCr
-2.58%+0.24%+18.54%+41.28% 3.56TCr
-1.76%-11.56%+126.44%+649.27% 3.46TCr
+0.10%-1.05%+76.50%+57.34% 3.25TCr
-1.69%-0.79%-40.58%+382.68% 2.63TCr
Average -0.61%-4.52%+27.48%+143.10% 4TCr
Weighted average by Cap. -0.88%-3.29%+33.56%+143.41%

Financials

2026 *2027 *
Net sales 2.06Cr 20.23L 18.45L 17.06L 15.39L 28.99L 19Cr 30.13L 81.43L 10Cr 75.89L 74.3L 32Cr 2.86Cr 28.13L 25.66L 23.72L 21.41L 40.32L 26Cr 41.91L 1.13Cr 14Cr 1.06Cr 1.03Cr 45Cr
Net income -9Cr -88.37L -80.6L -74.52L -67.25L -1.27Cr -83Cr -1.32Cr -3.56Cr -45Cr -3.32Cr -3.25Cr -140.75Cr -8.8Cr -86.36L -78.76L -72.82L -65.72L -1.24Cr -81Cr -1.29Cr -3.48Cr -44Cr -3.24Cr -3.17Cr -137.55Cr
Net Debt -8.04Cr -78.9L -71.95L -66.53L -60.04L -1.13Cr -74Cr -1.18Cr -3.18Cr -40Cr -2.96Cr -2.9Cr -125.66Cr -4.8Cr -47.13L -42.98L -39.74L -35.87L -67.55L -44Cr -70.21L -1.9Cr -24Cr -1.77Cr -1.73Cr -75Cr
Projected Income Statement - Annual - Intervacc AB
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
19/26/19 SEK 0.6900 +2.68% 18,000
18/26/18 SEK 0.6720 -3.03% 5,31,531
17/26/17 SEK 0.6930 -5.07% 3,20,181
16/26/16 SEK 0.7300 +8.31% 9,65,093
13/26/13 SEK 0.6740 -3.30% 13,99,509
  1. Stock Market
  2. Stocks
  3. IVACC Stock